Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6689225rdf:typepubmed:Citationlld:pubmed
pubmed-article:6689225lifeskim:mentionsumls-concept:C0004057lld:lifeskim
pubmed-article:6689225lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:6689225lifeskim:mentionsumls-concept:C0036079lld:lifeskim
pubmed-article:6689225lifeskim:mentionsumls-concept:C0178602lld:lifeskim
pubmed-article:6689225lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:6689225lifeskim:mentionsumls-concept:C0439064lld:lifeskim
pubmed-article:6689225lifeskim:mentionsumls-concept:C0068991lld:lifeskim
pubmed-article:6689225pubmed:issue4lld:pubmed
pubmed-article:6689225pubmed:dateCreated1984-2-24lld:pubmed
pubmed-article:6689225pubmed:abstractTextPlasma salicyclic acid levels from the recommended multiple dose regimen of Norgesic Forte (orphenadrine citrate, aspirin, and caffeine) were compared to those from an equivalent multiple dose regimen of aspirin alone in 24 volunteers. The drugs were administered double-blind so that side effects could also be compared. No statistically significant differences were found between Norgesic Forte and aspirin in peak or trough levels, time to peak level, area under the curve, or mean steady-state level of salicylic acid. Mean steady-state levels averaged 154 +/- 46 (+/- SD) and 152 +/- 49 micrograms/ml on days 5 and 10 following Norgesic Forte versus 161 +/- 49 and 154 +/- 47 micrograms/ml following aspirin. Thus, the aspirin in Norgesic Forte provides an anti-inflammatory amount of salicylic acid equivalent to that of plain aspirin. There was no evidence that the combination of orphenadrine citrate, caffeine, and aspirin in Norgesic Forte caused increased or unusual side effects compared with aspirin alone.lld:pubmed
pubmed-article:6689225pubmed:languageenglld:pubmed
pubmed-article:6689225pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6689225pubmed:citationSubsetIMlld:pubmed
pubmed-article:6689225pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6689225pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6689225pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6689225pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6689225pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6689225pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6689225pubmed:statusMEDLINElld:pubmed
pubmed-article:6689225pubmed:issn0163-4356lld:pubmed
pubmed-article:6689225pubmed:authorpubmed-author:HarrisonL ILIlld:pubmed
pubmed-article:6689225pubmed:authorpubmed-author:KvamD CDClld:pubmed
pubmed-article:6689225pubmed:authorpubmed-author:BianchineJ...lld:pubmed
pubmed-article:6689225pubmed:authorpubmed-author:GoldlustM BMBlld:pubmed
pubmed-article:6689225pubmed:authorpubmed-author:KeheC RCRlld:pubmed
pubmed-article:6689225pubmed:issnTypePrintlld:pubmed
pubmed-article:6689225pubmed:volume5lld:pubmed
pubmed-article:6689225pubmed:ownerNLMlld:pubmed
pubmed-article:6689225pubmed:authorsCompleteYlld:pubmed
pubmed-article:6689225pubmed:pagination401-4lld:pubmed
pubmed-article:6689225pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:6689225pubmed:meshHeadingpubmed-meshheading:6689225-...lld:pubmed
pubmed-article:6689225pubmed:meshHeadingpubmed-meshheading:6689225-...lld:pubmed
pubmed-article:6689225pubmed:meshHeadingpubmed-meshheading:6689225-...lld:pubmed
pubmed-article:6689225pubmed:meshHeadingpubmed-meshheading:6689225-...lld:pubmed
pubmed-article:6689225pubmed:meshHeadingpubmed-meshheading:6689225-...lld:pubmed
pubmed-article:6689225pubmed:meshHeadingpubmed-meshheading:6689225-...lld:pubmed
pubmed-article:6689225pubmed:meshHeadingpubmed-meshheading:6689225-...lld:pubmed
pubmed-article:6689225pubmed:meshHeadingpubmed-meshheading:6689225-...lld:pubmed
pubmed-article:6689225pubmed:meshHeadingpubmed-meshheading:6689225-...lld:pubmed
pubmed-article:6689225pubmed:meshHeadingpubmed-meshheading:6689225-...lld:pubmed
pubmed-article:6689225pubmed:meshHeadingpubmed-meshheading:6689225-...lld:pubmed
pubmed-article:6689225pubmed:meshHeadingpubmed-meshheading:6689225-...lld:pubmed
pubmed-article:6689225pubmed:year1983lld:pubmed
pubmed-article:6689225pubmed:articleTitleSalicylic acid plasma levels following multiple doses of Norgesic Forte and aspirin.lld:pubmed
pubmed-article:6689225pubmed:publicationTypeJournal Articlelld:pubmed